Recent proof-backed calls
No active analyst plays. Internal coverage recently referenced BEAM in 'Big Ideas 2026: Multiomics.'
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
Short listing for a YouTube interview filmed at the 2026 Abundance360 Summit with Ben Lamm (Colossal) titled “AI + Synthetic Biology: The Most Transformative Technology in Human History.” The listing notes the video but the transcript could not be retrieved. Content likely promotes Colossal’s synthetic biology/de‑extinction work and argues AI+synthbio is transformational. No new corporate filings, financing, or measurable operational updates are present in the item.
Latest market-close explanation
On 2026-04-13 BEAM rose 10.03%, closing at $30.18 (prior close $27.43). Intraday range $27.47–$30.56 and volume was up 66.7% versus the prior session. The company was also mentioned in internal research 'Big Ideas 2026: Multiomics.'
**BEAM** (Beam Therapeutics Inc.) moved **+10.03%** on 2026-04-13, closing at **$30.18** after a previous close of **$27.43**. Intraday range was **$27.47** to **$30.56**. Volume changed **+66.7%** versus the prior session. Recent internal coverage also touched BEAM: **Big Ideas 2026: Multiomics**.
Current stance
No current formal recommendation is provided for BEAM on this page.
Top authors on this ticker
Active and historical plays
There are no active plays for BEAM at this time.
Unlock full ticker monitoring
For more detail, consult the linked research items and the full 'Big Ideas 2026' coverage.